iCAD, Inc. has completed the previously announced acquisition of Xoft, Inc., developer of the Axxent® eBx™ electronic brachytherapy system. The portable Axxent System treats early stage breast cancer, endometrial cancer, and skin cancer, and other cancers and conditions where radiation therapy is indicated.
“Our new combined company is well positioned for long-term growth and to accelerate the adoption of new standards of care in oncology,” said Ken Ferry, president and CEO of iCAD. “By combining our innovative solutions, iCAD and Xoft can empower clinicians to improve patient outcomes through collaborative delivery of more targeted cancer detection, diagnosis, treatment, and monitoring.”
“Xoft’s technology expands patient access to potentially lifesaving treatments globally and provides a compelling treatment alternative to traditional external beam radiation, which is administered five days per week over a six to seven week timeframe,” said Michael Klein, former president and CEO of Xoft. “We are excited to join with iCAD on our mission to increase access to targeted radiation therapy, improve patient outcomes, and better the experience for patients during their cancer treatments.”